Skip to main content

Advertisement

SpringerLink
Log in

Survivin and Caspase-3 Cannot Predict Recurrence for Urinary Bladder Carcinoma

  • Original Paper
  • Published:
SN Comprehensive Clinical Medicine Aims and scope Submit manuscript

Abstract

Bladder cancer is a major health problem. The limitations of poor sensitivity of cytology and the invasiveness of cystoscopy have generated interest in other non-invasive tools to monitor tumor recurrence. The measurement of survivin can aid the early diagnosis of bladder cancer, determine prognosis, and predict treatment outcomes. Its combination with other biomarkers as caspase-3 in this study may enhance prognostication and prediction of treatment response in bladder cancer, as well as tumor recurrence. The present study included 51 prospective consecutive patients undergoing transurethral resection of a bladder tumor (TURBT) for suspected bladder cancer. Immunohistochemical (IHC) staining and scoring for survivin and caspase-3 were done and then correlated with available clinical parameters. Seven patients had no cancer diagnosis, and none of them had positive immunoreactivity. Forty-four patients had bladder cancer, and expression of survivin and caspase-3 was present in 42 (95.5%) and 10 (22.7%) cases, respectively. There was no statistically significant correlation between recurrence and either survivin or caspase-3 expression. Survivin and/ or caspase-3 is not recommended as a part of the workup for bladder cancer, as their clinical applicability is very doubtful.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data Availability

Data are stored in the Pathology Department of Alexandria University and can be accessed, if needed.

Code Availability

N/A.

Abbreviations

TURBT :

Transurethral resection of a bladder tumor

IHC :

Immunohistochemistry

IAP :

Inhibitor of apoptosis protein

UCB :

Urothelial carcinoma of the bladder

UICC :

Union International Contre le Cancer

TNM :

Tumor, nodes, metastases

References

  1. Martin M, Domenech J, Schmidt O, et al. Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol Semin Orig Invest. 2010;28(4):401–8.

    Google Scholar 

  2. Shariat S, Casella R, Khoddami S, et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol Am Urol Assoc. 2004;171:626–30.

    CAS  Google Scholar 

  3. Shariat S, Tokunaga H, Zhou J, et al. P53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004;22:1014–24.

    Article  CAS  Google Scholar 

  4. Gopisetty G, Ramachandran K, Singal R. DNA methylation and apoptosis. Mol Immunol. 2006;43(11):1729–40.

    Article  CAS  Google Scholar 

  5. Shariat S, Kim J, Raptidis G, et al. Association of P53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology. 2003;61:1140–5.

    Article  Google Scholar 

  6. Salvesen G, Duckett C. IAP proteins: blocking the road to death’s door. Nat Rev Mol Cell Biol. 2002;3:401–10.

    Article  CAS  Google Scholar 

  7. Nicholson D. From bench to clinic with apoptosis-based therapeutic agents. Nature. 2000;407:810–6.

    Article  CAS  Google Scholar 

  8. Adida C, Crotty P, McGrath J, et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol. 1998;152:43–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Ryan B, O’Donovan N, Duffy M. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev. 2009;35(7):553–652.

    Article  CAS  Google Scholar 

  10. Altieri D. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22:8581–9.

    Article  CAS  Google Scholar 

  11. Shariat S, Chade D, Karakiewicz P, et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010;183:68–75.

    Article  Google Scholar 

  12. Shariat S, Karakiewicz P, Godoy G, et al. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res. 2009;15:7012.

    Article  CAS  Google Scholar 

  13. Karam J, Lotan Y, Karakiewicz P, et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 2007;8(2):128–36.

    Article  CAS  Google Scholar 

  14. Shariat S, Karam J, Lerner S. Molecular markers in bladder cancer. Curr Opin Urol. 2008;18:1–8.

    Article  Google Scholar 

  15. Shariat S, Ashfaq R, Sagalowsky A, et al. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol. 2007;177:481–7.

    Article  Google Scholar 

  16. Ku J, Kwak C, Lee H, et al. Expression of survivin, a novel in inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol. 2004;171(2Pt1):631–5.

    Article  CAS  Google Scholar 

  17. Hou J, He J, Wen D, et al. Survivin mRNA expression in urine as a biomarker for patients with transitional cell carcinoma of bladder. Chin Med J. 2006;119(13):1118–20.

    Article  CAS  Google Scholar 

  18. Swana H, Grossman D, Anthony J, et al. Tumor content of the anti-apoptosis molecule survivin and recurrence of bladder cancer. New Engl J Med. 1999;341:452–3.

    Article  CAS  Google Scholar 

  19. Fortugno P, Wall N, Giodini A, et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci. 2002;115:575–85.

    Article  CAS  Google Scholar 

  20. Kawasaki H, Altieri D, Lu C, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58:5071–4.

    CAS  PubMed  Google Scholar 

  21. Lu C, Atieri D, Kawasaki H, et al. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998;58:1808–12.

    CAS  PubMed  Google Scholar 

  22. Adida C, Berrebi D, Peuchmaur M, et al. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet. 1998;351:882–3.

    Article  CAS  Google Scholar 

  23. Saito T, Arifin M, Hama S, et al. Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker. J Neurooncol. 2007;82:193–8.

    Article  CAS  Google Scholar 

  24. Burton P, Anderson C, Corbishly CM. Caspase 3 and p27 as predictors of invasive bladder cancer. N Engl J Med. 2000;343:1418–20.

    Article  CAS  Google Scholar 

  25. Engels K, Knauer S, Metzler D, et al. Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J Pathol. 2007;211:532–40.

    Article  CAS  Google Scholar 

  26. Muris J, Cillessen S, Vos W, et al. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood. 2005;105(7):2916–23.

    Article  CAS  Google Scholar 

  27. Krajewska M, Wang H, Krajewski S, et al. Immunohistochemical analysis of in vivo patterns of expression of CPP32 (caspase-3), a cell death protease. Cancer Res. 1997;57:1605–13.

    CAS  PubMed  Google Scholar 

  28. Kobayashi T, Masumoto J, Tada T, et al. Prognostic significance of the immunohistochemical staining of cleaved caspase-3, an activated form of caspase-3, in gliomas. Clin Cancer Res. 2007;13:3868–74.

    Article  CAS  Google Scholar 

  29. Winter R, Kramer A, Borkowski A, et al. Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res. 2001;61:1227–32.

    CAS  PubMed  Google Scholar 

  30. Giannopoulou I, Nakopoulou L, Zervas A, et al. Immunohistochemical study of proapoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications. Urol Res. 2002;30:342–5.

    Article  CAS  Google Scholar 

  31. Wang J, Lenardo M. Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. J Cell Sci. 2000;113:753–7.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pathology Department, Ministry of Health, Cairo, Egypt

    Vivian G. D. Rouston

  2. Pathology Department, Alexandria University, Alexandria, Egypt

    Amal A. A. Shaaban & Dina M. Abd Allah

  3. Urology Department, Northern Ontario School of Medicine, Thunder Bay, Canada

    Ahmed F. Kotb

  4. TBRHSC, 980 Oliver Road, Thunder Bay, ON, P7B 6V4, Canada

    Ahmed F. Kotb

Authors
  1. Vivian G. D. Rouston
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amal A. A. Shaaban
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dina M. Abd Allah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ahmed F. Kotb
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Vivian GD Rouston: data collection and analysis and manuscript writing

Amal AA Shaaban: study design, data analysis, and manuscript revision

Dina M Abd Allah: study design, data analysis, and manuscript revision

Ahmed F Kotb: study design, data collection, and manuscript writing and revision.

Corresponding author

Correspondence to Ahmed F. Kotb.

Ethics declarations

Ethics Approval and Consent to Participate

Institutional ethical approval was obtained. All patients were consented by the principal investigator for data collection and publication without patients’ identifiers.

Consent for Publication

All patients were consented for data collection and publication.

Competing Interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Surgery

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rouston, V.G.D., Shaaban, A.A.A., Abd Allah, D.M. et al. Survivin and Caspase-3 Cannot Predict Recurrence for Urinary Bladder Carcinoma. SN Compr. Clin. Med. 3, 2292–2300 (2021). https://doi.org/10.1007/s42399-021-01052-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s42399-021-01052-6

Keyword

Search

Navigation